Ketorolac Trometamol Misom (Ketorolac Trometamol)

The drug inhibits both COX‑1 and COX‑2 enzymes in ocular tissues, which blocks the formation of prostaglandins. By lowering prostaglandin levels, it reduces inflammation, vasodilation and pain signals, providing therapeutic relief in the treated eye.

The dosing regimen is determined by the prescribing ophthalmologist based on the specific surgical procedure and patient response. The prescriber will indicate the number of drops, frequency and duration of treatment on the prescription label.

Safety data for ketorolac trometamol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ketorolac is a non‑steroidal anti‑inflammatory eye drop that offers rapid pain relief without the steroid‑related risks of cataract formation or intra‑ocular pressure rise. Compared with corticosteroid drops, it has a lower risk of steroid‑induced side effects but may be less potent for severe inflammation.

The ophthalmic solution should be stored at room temperature, preferably below 25 °C, in its original container. Protect it from direct light, moisture and extreme temperatures. Keep the bottle tightly closed when not in use.

The medication is applied as eye drops. The prescriber will instruct the patient on the number of drops per eye, the frequency (e.g., one drop every 4–6 hours), and the total duration of therapy. Patients should avoid touching the tip of the bottle to the eye or any surface.

Serious risks include corneal ulceration, severe allergic reactions such as anaphylaxis, marked increase in intra‑ocular pressure, and rare systemic hypersensitivity reactions. Patients should be instructed to seek immediate medical attention if they experience sudden vision loss, severe eye pain, or signs of an allergic reaction.

Individuals with a known hypersensitivity to ketorolac, other NSAIDs, or any component of the formulation should avoid this product. It is also contraindicated in patients with active corneal epithelial defects or those for whom prolonged NSAID use is medically inadvisable.